Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Authors' conclusion
Results from this EMPRISE Europe and Asia study complements previous clinical trials and real-world studies by providing further evidence of the beneficial cardiorenal effects and overall safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors.
Study context
- Population
- Patients with T2D initiating empagliflozin or DPP-4i, data 2014–2019 from Denmark, Finland, Germany, Norway, Spain, Sweden, UK, Israel, Japan, South Korea, Taiwan83,946 matched pairs
- Exposure
- Empagliflozin vs DPP-4i initiation
- Outcome
- Hospitalization for HF, all-cause mortality, MI and stroke
- Follow-up
- 0.7 years overall mean
Methodological details1:1 propensity score matched, multinational (7 European and 4 Asian countries)
- 1:1 propensity score matched
- Multinational (7 European and 4 Asian countries)
Main finding
As reported in the abstract
Primary endpoints
Estimate (95% CI)
Empagliflozinvs DPP-4i
HR (hospitalization for HF) 0.70(0.60–0.83)
Empagliflozinvs DPP-4i
HR (all-cause mortality) 0.55(0.48–0.63)
Empagliflozinvs DPP-4i
HR (stroke) 0.82(0.71–0.96)
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | |
|---|---|---|
| End-stage renal diseaseEmpagliflozinvs DPP-4i | 0.43 (0.30–0.63) | |
| 0.20.5125Hazard ratio (log scale) |
Consistency by region
- Results were consistent across continents and regions
Safety
| Outcome | HR (CI) | |
|---|---|---|
| DKAEmpagliflozinvs DPP-4i | 1.97 (1.28–3.03) | |
| 0.20.5125Hazard ratio (log scale) |
Bone fracture, severe hypoglycemia, lower-limb amputation
- Risks of bone fracture, severe hypoglycemia and lower-limb amputation similar between groups
Original publication
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Metab. Published 3 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →